Amir Nashat is a partner in our Boston office. Amir joined Polaris in April 2002 and focuses on investments in healthcare, consumer products and energy.
Prior to joining Polaris, Amir completed his PhD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. During his time at MIT, Amir completed an internship in the London office of Goldman, Sachs & Company. Amir has also served as the initial CEO of Living Proof (known as Andora at the time), and Sun Catalytix Corporation. Prior to MIT, Amir earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.
Amir currently represents Polaris as a Director of aTyr Pharmaceuticals, BIND Biosciences, Fate Therapeutics, Promedior Pharmaceuticals, Receptos and Selecta Biosciences. Additionally, Amir has served as a Director of Adnexus Therapeutics (acquired by Bristol Myers Squibb), Athenix Corporation (acquired b Bayer), Avila Therapeutics (acquired by Celgene), Living Proof, Pervasis Therapeutics (acquired by Shire Pharmaceuticals), and served as a Board Observer of GI Dynamics (GID.AX).
Amir serves on the Partners Innovation Fund and is a Catalyst of the Deshpande Center for Technological Innovation at MIT. He previously served on the Board of the New England Venture Capital Association.
New England Venture Capital Association, Board Member (Former)
Deshpande Center for Technological Innovation, MIT, Member
Partners Innovation Fund Investment Committee, Member
B.S., M.S., University of California, Berkeley
Ph.D., Massachusetts Institute of Technology